Who
Tom Frohlich
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Jade Biosciences; Chief Operating Officer, Chinook Therapeutics.
In numbers
- Trades disclosed
- 58
- Buys
- 1
- Sells
- 10
- Bought
- $44K
- Sold
- $1.7M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 5 Oct 2020
- Last trade
- 12 Feb 2026
- Last filed
- 13 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Feb 2026filed 13 Feb 2026 | JBIO Jade BiosciencesBiotechnology | SEC FORM 4 Code A | —78,750 at $0.00 | filing |
| 12 Feb 2026filed 13 Feb 2026 | JBIO Jade Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —472,500 at $0.00 | filing |
| 12 Feb 2026filed 13 Feb 2026 | JBIO Jade Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —472,500 at $0.00 | filing |
| 12 Feb 2026filed 13 Feb 2026 | JBIO Jade BiosciencesBiotechnology | SEC FORM 4 Code A | —78,750 at $0.00 | filing |
| 16 May 2025filed 19 May 2025 | JBIO Jade BiosciencesBiotechnology | SEC FORM 4 Bought | $44K6,000 at $7.40 | filing |
| 11 Aug 2023filed 11 Aug 2023 | Chinook Therapeuticsoption or derivative | SEC FORM 4 Code D | $1.7M43,847 at $39.58 | filing |
| 11 Aug 2023filed 11 Aug 2023 | Chinook Therapeuticsoption or derivative | SEC FORM 4 Code D | $3.0M119,793 at $25.23 | filing |
| 11 Aug 2023filed 11 Aug 2023 | Chinook Therapeuticsoption or derivative | SEC FORM 4 Code D | $1.5M60,000 at $24.86 | filing |
| 11 Aug 2023filed 11 Aug 2023 | Chinook Therapeuticsoption or derivative | SEC FORM 4 Code D | $672K30,000 at $22.41 | filing |
| 11 Aug 2023filed 11 Aug 2023 | Chinook Therapeuticsoption or derivative | SEC FORM 4 Code D | $2.7M100,000 at $27.10 | filing |
| 11 Aug 2023filed 11 Aug 2023 | Chinook Therapeuticsoption or derivative | SEC FORM 4 Code D | $1.2M84,000 at $14.73 | filing |
| 11 Aug 2023filed 11 Aug 2023 | Chinook Therapeuticsoption or derivative | SEC FORM 4 Code D | —13,581 | filing |
| 11 Aug 2023filed 11 Aug 2023 | Chinook Therapeuticsoption or derivative | SEC FORM 4 Code D | —6,801 | filing |
| 11 Aug 2023filed 11 Aug 2023 | Chinook Therapeuticsoption or derivative | SEC FORM 4 Code D | —16,667 | filing |
| 11 Aug 2023filed 11 Aug 2023 | Chinook Therapeuticsoption or derivative | SEC FORM 4 Code D | —21,000 | filing |
| 11 Aug 2023filed 11 Aug 2023 | Chinook Therapeuticsoption or derivative | SEC FORM 4 Code D | —8,400 | filing |
| 11 Aug 2023filed 11 Aug 2023 | Chinook Therapeutics | SEC FORM 4 Code D | —150,777 | filing |
| 10 Feb 2023filed 15 Feb 2023 | Chinook Therapeuticsoption or derivative | SEC FORM 4 Code M | —6,803 at $0.00 | filing |
| 10 Feb 2023filed 15 Feb 2023 | Chinook Therapeutics | SEC FORM 4 Code M | —6,803 | filing |
| 10 Feb 2023filed 15 Feb 2023 | Chinook Therapeutics | SEC FORM 4 Sold | $88K3,700 at $23.75 | filing |
News
Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026JBIO · manilatimes.net · 21 Oct 2026
0 headlines in the last 90 days name Tom Frohlich; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.